Skip to content
paul_cornes_bw

Affiliation

Comparative Outcomes Group, Bristol UK

Country

United Kingdom

1. Current Status, Position

Dr Paul Cornes (BM BCH MA MRCP FRCR) is an Oncologist from Bristol, UK.

2. Education

Dr Paul Cornes trained in Medicine at Oxford University and in Oncology at the Royal Marsden Hospital, London, UK before becoming a Consultant Oncologist in Bristol, UK.

3. Research Area

Dr Paul Cornes is part of the steering group for the European School of Oncology Working Party on the Access to Innovation in Cancer Treatment. He was part of the team that developed and presented evidence to the Oncology Advisory drugs Committee of the FDA for the first successfully approved US biosimilar. He has been in the British Medical Journal’s “Round Table” group on Biosimilars and has been on the panel for the EU Commission biosimilars meeting in Brussels.

4. Conflict of interest: Dr Paul Cornes received honoraria from the following companies for speaking at meetings in 2016:

  • Amgen
  • Generic and Biosimilar Medecines Association – Australia
  • Merck Serono
  • Napp
  • Sandoz
×

Deadline extended to July 15th

Problems caused by shortages are serious, threaten patient care and require urgent action.

Help us provide an overview of the scale of the problem, as well as insights into the impact on overall patient care.

Our aim is to investigate the causes of medicine and medical device shortages in the hospital setting,  while also gathering effective solutions and best practices implemented at local, regional, and national levels.

×

Join us in Prague for the 2nd edition of BOOST!

Secure your spot in the Movement for Shortage-Free World

BOOST is where visionaries, innovators, and healthcare leaders come together to tackle one of the biggest challenges in hospital pharmacy—medicine shortages.